These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 1498863

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The effects of brofaromine, a reversible MAO-A inhibitor, on extracellular serotonin in the raphe nuclei and frontal cortex of freely moving rats.
    Celada P, Bel N, Artigas F.
    J Neural Transm Suppl; 1994; 41():357-63. PubMed ID: 7931251
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Brofaromine--a review of its pharmacological properties and therapeutic use.
    Volz HP, Gleiter CH, Waldmeier PC, Struck M, Möller HJ.
    J Neural Transm (Vienna); 1996; 103(1-2):217-45. PubMed ID: 9026374
    [Abstract] [Full Text] [Related]

  • 7. Comparison of neurochemical effects of the monoamine oxidase inhibitors phenelzine, moclobemide and brofaromine in the rat after short- and long-term administration.
    Urichuk LJ, Allison K, Holt A, Greenshaw AJ, Baker GB.
    J Affect Disord; 2000 May; 58(2):135-44. PubMed ID: 10781703
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Monoamine oxidase inhibitors phenelzine and brofaromine increase plasma serotonin and decrease 5-hydroxyindoleacetic acid in patients with major depression: relationship to clinical improvement.
    Celada P, Pérez J, Alvarez E, Artigas F.
    J Clin Psychopharmacol; 1992 Oct; 12(5):309-15. PubMed ID: 1282522
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Brofaromine--a selective, reversible, and short-acting MAO-A inhibitor: review of the pharmacological and clinical findings.
    Möller HJ, Wendt G, Waldmeier P.
    Pharmacopsychiatry; 1991 Mar; 24(2):50-4. PubMed ID: 1852792
    [Abstract] [Full Text] [Related]

  • 13. Enhancement of 5-HT-induced anorexia: a test of the reversibility of monoamine oxidase inhibitors.
    Fletcher PJ, Yu PH.
    Psychopharmacology (Berl); 1989 Mar; 98(2):265-8. PubMed ID: 2502797
    [Abstract] [Full Text] [Related]

  • 14. Is phentermine an inhibitor of monoamine oxidase? A critical appraisal.
    Rothman RB.
    Synapse; 1999 May; 32(2):141-5. PubMed ID: 10231134
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of rat brainstem monoamine oxidase activity by CGP 6085 A.
    Hurst JH, Kulakowski EC.
    Life Sci; 1986 Oct 20; 39(16):1471-7. PubMed ID: 2430159
    [Abstract] [Full Text] [Related]

  • 16. Effects of CGP 11305 A, a new reversible and selective inhibitor of MAO A, on biogenic amine levels and metabolism in the rat brain.
    Waldmeier PC, Baumann PA.
    Naunyn Schmiedebergs Arch Pharmacol; 1983 Sep 20; 324(1):20-6. PubMed ID: 6195533
    [Abstract] [Full Text] [Related]

  • 17. Regional 5-HT analysis in Roman high- and low-avoidance rats following MAO inhibition.
    Driscoll P, Dedek J, Martin JR, Baettig K.
    Eur J Pharmacol; 1980 Dec 05; 68(3):373-6. PubMed ID: 6162652
    [Abstract] [Full Text] [Related]

  • 18. The effects of 5-HT uptake- and MAO-inhibitors on L-5-HTP-induced excitation in rats.
    Ortmann R, Waldmeier PC, Radeke E, Felner A, Delini-Stula A.
    Naunyn Schmiedebergs Arch Pharmacol; 1980 Mar 05; 311(2):185-92. PubMed ID: 6966764
    [Abstract] [Full Text] [Related]

  • 19. The inhibition of monoamine oxidase by brofaromine.
    Anderson MC, Waldmeier PC, Tipton KF.
    Biochem Pharmacol; 1991 Jun 15; 41(12):1871-7. PubMed ID: 2039542
    [Abstract] [Full Text] [Related]

  • 20. The effect of the MAO-A selective inhibitor brofaromine on the plasma and urine concentrations of some biogenic amines and their acidic metabolites in bulimia nervosa.
    Davis BA, Kennedy SH, Durden DA, D'Souza J, Goldbloom DS, Boulton AA.
    Prog Neuropsychopharmacol Biol Psychiatry; 1993 Sep 15; 17(5):747-63. PubMed ID: 7504824
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.